The high sensitivity to increased B55α expression in PC3 and DU145 cells, but not other cancer cell lines and normal BJ-fibroblasts, exposes a susceptibility that could potentially be targeted pharmacologically by PP2A activating drugs with preference for B55 family PP2A holoenzymes. The gene discussed is PPP2R2A; the disease is cancer.